Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

[1]  M. Piccart,et al.  Flexible care in breast cancer , 2021, ESMO open.

[2]  A. Tan,et al.  Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. , 2020, The Lancet. Oncology.

[3]  Aina Abell.  FDA approves breast cancer treatment that can be administered at home , 2020 .

[4]  R. Nelson,et al.  The oncology hospital at home: Health care utilization outcomes from the huntsman at home trial. , 2020 .

[5]  Iris Usach,et al.  Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site , 2019, Advances in Therapy.

[6]  E. Winer,et al.  Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R Smith,et al.  Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Verma,et al.  A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer , 2016, Cancer medicine.

[9]  L. Zelek,et al.  Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  L. Fallowfield,et al.  Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. , 2013, The Lancet. Oncology.

[11]  D. Anderson,et al.  Catheter-associated thrombosis in patients with malignancy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Bemelman,et al.  Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. , 1996, European journal of cancer.

[13]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[15]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .